IMUX

Company Overview — What Does IMMUNIC, INC. Do?

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York. IMMUNIC, INC. (IMUX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel Vitt and employs approximately 70 people, headquartered in New York, , United States. With a market capitalization of $150M, IMUX is one of the notable companies in the Healthcare sector.

IMMUNIC, INC. (IMUX) Stock Rating — Reduce (April 2026)

As of April 2026, IMMUNIC, INC. receives a Reduce rating with a composite score of 29.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IMUX ranks #3,178 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IMMUNIC, INC. ranks #476 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMUX Stock Price and 52-Week Range

IMMUNIC, INC. (IMUX) currently trades at $1.17. The stock lost $0.12 (9.3%) in the most recent trading session. The 52-week high for IMUX is $1.51, which means the stock is currently trading -22.5% from its annual peak. The 52-week low is $0.51, putting the stock 131.1% above its annual trough. Recent trading volume was 2.0M shares, reflecting moderate market activity.

Is IMUX Overvalued or Undervalued? — Valuation Analysis

IMMUNIC, INC. (IMUX) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 18.02x, versus the sector average of 2.75x.

At current multiples, IMMUNIC, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IMMUNIC, INC. Profitability — ROE, Margins, and Quality Score

IMMUNIC, INC. (IMUX) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -973.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -425.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMUX Debt, Balance Sheet, and Financial Health

IMMUNIC, INC. has a debt-to-equity ratio of 288.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.75x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $35M.

IMUX has a beta of 1.07, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for IMMUNIC, INC. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

IMMUNIC, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, IMMUNIC, INC. reported revenue of $0 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-102M. Operating income came in at $-106M.

In FY 2025, IMMUNIC, INC. reported revenue of $0 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-97M. Operating income came in at $-103M.

In Q3 2025, IMMUNIC, INC. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-26M. Operating income came in at $-26M.

In Q2 2025, IMMUNIC, INC. reported revenue of $0 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-27M. Operating income came in at $-27M.

Over the past 8 quarters, IMMUNIC, INC. has experienced revenue contraction from $0 to $0. Investors analyzing IMUX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMUX Dividend Yield and Income Analysis

IMMUNIC, INC. (IMUX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMUX Momentum and Technical Analysis Profile

IMMUNIC, INC. (IMUX) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

IMUX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IMMUNIC, INC. (IMUX) ranks #476 out of 838 stocks based on the Blank Capital composite score. This places IMUX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMUX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMUX vs S&P 500 (SPY) comparison to assess how IMMUNIC, INC. stacks up against the broader market across all factor dimensions.

IMUX Next Earnings Date

No upcoming earnings date has been announced for IMMUNIC, INC. (IMUX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMUX? — Investment Thesis Summary

The quantitative profile for IMMUNIC, INC. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. High volatility (stability score 29/100) increases portfolio risk.

In summary, IMMUNIC, INC. (IMUX) earns a Reduce rating with a composite score of 29.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMUX stock.

Related Resources for IMUX Investors

Explore more research and tools: IMUX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMUX head-to-head with peers: IMUX vs AZN, IMUX vs SLGL, IMUX vs VMD.